Glaxosmithkline Share News (GSK)

Genmab announces positive results for sclerosis drug candidate

COPENHAGEN, Oct 10 (Reuters) - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab. In a randomised study of 232 patients with relapsing-remitting multiple sclerosis, treatment with ofatumumab significantly redu

DIRECTOR DEALINGS: Glaxo Directors Buy Shares

FTSE 100 movers: Persimmon boosted by 'Help to Buy' confidence

House builder Persimmon was a high riser this afternoon as optimism over the government's 'Help to Buy' scheme continues to help the stock bounce off recent lows. The share price has now gained over 10 per cent over the last two days. Whitbread shares leapt on market chatter about a potential spin-

German watchdog urges greater EU drug trial transparency

DIRECTOR DEALINGS: GlaxoSmithKline CEO, Executive Directors, Managers Awarded Shares

BROKER RATING CHANGES: Investec Raises Lloyds Banking To Buy From Hold

Teva sees obstacles to copying GSK's Advair drug before 2018

LONDON, Oct 8 (Reuters) - Teva Pharmaceuticals does not expect to see the launch of generic copies of GlaxoSmithKline's best-selling lung drug Advair that could be sold as a true substitute to U.S. patients before 2018. The cautious comments by the world's biggest maker of generic medicine

DIRECTOR DEALINGS: GlaxoSmithKline Company Secretary Reinvests Dividend

GlaxoSmithKline applies for malaria vaccine approval in 2015

The world's first malaria vaccine could be on the market as early as 2015, GlaxoSmithKline said after its advanced clinical trials proved encouraging. The FTSE 100 company's large-scale Phase III clinical trial showed its experimental malaria vaccine candidate helped reduce cases of the disease in

Indian stocks to watch - Oct 8

Oct 8 (Reuters) - GLOBAL MARKETS ROUNDUP * Nifty futures on the Singapore Exchange are up 0.85 percent, while the MSCI-Asia Pacific index excluding Japan is flat. * The dollar skidded to near an eight-month low on Tuesday as the U.S. government shutdown entered its second w

DIRECTOR DEALINGS: GlaxoSmithKline CEO, Managers Purchase Shares

GlaxoSmithKline India hit by drop in bulk orders

By Sumeet Chatterjee Oct 7 (Reuters) - GlaxoSmithKline's Indian business has been hit by a drop in sales which two industry sources said was linked to a protest by bulk buyers against a cut in their profit margins under a new government drug pricing policy. GlaxoSmithKline Pharmaceuti

London close: Markets in 'wait-and-see' mode as shutdown continues

After fluctuating between gains and losses for most of the day, the FTSE 100 finished broadly flat on Friday as stocks struggled for direction. In the absence of economic news and ongoing political uncertainty in the States, markets remain in "wait-and-see mode", according Senior Market Analyst Mic

DIRECTOR DEALINGS: GlaxoSmithKline Executives Acquire Shares

Broker tips: Barclays, GlaxoSmithKline, Tate & Lyle

Investec has raised its recommendation for banking group Barclays from 'add' to 'buy' and retained its 300p target price despite what is expected to be a 'lacklustre' third-quarter report on October 30th. Analyst Ian Gordon said that the upgrade is due to a combination of: passing rights issues-rel